Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

Immune checkpoint inhibitors have significantly improved overall survival with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients. However, not all patients are sensitive to immune checkpoint blockade and, in some cases, programmed death 1 (PD-1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazzari, Chiara, Karachaliou, Niki, Bulotta, Alessandra, Viganó, Mariagrazia, Mirabile, Aurora, Brioschi, Elena, Santarpia, Mariacarmela, Gianni, Luca, Rosell, Rafael, Gregorc, Vanesa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894901/
https://www.ncbi.nlm.nih.gov/pubmed/29662546
http://dx.doi.org/10.1177/1758835918762094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894901/
https://www.ncbi.nlm.nih.gov/pubmed/29662546
http://dx.doi.org/10.1177/1758835918762094

Ejemplares similares